Background: Obesity can influence the structure and function of the atrium, but most studies focused on the relationship of body mass index (BMI) and overt left atrium (LA) dysfunction as assessed by clinical imaging. We combined the assessment of right atrium (RA) function in vivo and in vitro in obese and non-obese patients scheduled for elective cardiac surgery.Methods: Atrial structure and function were quantified pre-operatively by echocardiography. RA tissue removed for the establishment of extracorporeal support was collected and RA trabeculae function was quantified in vitro at baseline and with adrenergic stimulation (isoproterenol). Fatty acid-binding protein 3 (FABP3) was quantified in RA tissue. Results were stratified according to the BMI of the patients.Results: About 76 patients were included pre-operatively for the echocardiographic analysis. RA trabeculae function at baseline was finally quantified from 46 patients and RA function in 28 patients was also assessed with isoproterenol. There was no significant correlation between BMI and the parameters of atrial function measured by the clinical echocardiography. However, in vitro measurements revealed a significant correlation between BMI and a prolonged relaxation of the atrial myocardium at baseline, which persisted after controlling for the atrial fibrillation and diabetes by the partial correlation analysis. Acceleration of relaxation with isoproterenol was significantly lower in the obese group (BMI ≥ 30 kg/m2). As a result, relaxation with adrenergic stimulation in the obese group remained significantly higher compared to the overweight group (25 kg/m2 ≤ BMI < 30 kg/m2, p = 0.027) and normal group (18.5 kg/m2 ≤ BMI < 25 kg/m2, p = 0.036). There were no differences on impacts of the isoproterenol on (systolic) developed force between groups. The expression of FABP3 in the obese group was significantly higher compared to the normal group (p = 0.049) and the correlation analysis showed the significant correlations between the level of FABP3 in the RA trabeculae function.Conclusion: A higher BMI is associated with the early subclinical changes of RA myocardial function with the slowed relaxation and reduced adrenergic lusitropy.

OBJECTIVES The choice of prosthesis for aortic valve replacement (AVR) in younger patients remains controversial. Stentless AVR was introduced 3 decades ago, with the aim of better haemodynamics and durability than stented xenografts. The objective of this analysis was to compare the long-term outcomes to mechanical prostheses in younger patients (age ≤60 years). METHODS All adult patients who underwent AVR due to aortic valve stenosis and/or insufficiency between 1993 and 2002 were identified. After the exclusion of patients with congenital heart defects, aortic dissections and Ross-procedures, 158 patients with stentless valves and 226 patients with bi-leaflet mechanical valves were finally included in this analysis. Sixty-six patient pairs could be included in a propensity matched analysis. Mortality and morbidity including stroke, bleeding, endocarditis and reoperation were analysed. RESULTS Group baseline characteristics and operative data did not differ significantly after propensity matching. Hospital mortality was 0.0% in the stentless and 1.5% in the mechanical group. Total patient years/median follow-up was 2029.1/15.4 years (completeness: 100.0%, range: 0-25 years). After 20 years, actuarial survival was 47.0 ± 6.4% in the stentless and 53.3 ± 6.6% in mechanical group (P = 0.69). Bleeding, endocarditis and stroke occurred rarely and did not differ significantly between groups. After 20 years, actuarial overall freedom-from-reoperation was 45.1 ± 8.2% in the stentless group and 90.4 ± 4.1% in the mechanical group (P < 0.001). Hospital mortality while reoperation was 7.4% in the stentless group and 0% in the mechanical group (P = 1.0). CONCLUSIONS Long-term morbidity and mortality of stentless and mechanical aortic valves were statistically not different besides a significantly higher reoperation rate after stentless AVR combined with a probably higher risk of in-hospital mortality. Thus, mechanical AVR should remain the procedure of choice in younger patients.

Purpose Surgical treatment of patients with renal cell carcinoma (RCC) and an extended tumour thrombus (TT) in the inferior vena cava (IVC) is challenging and often requires a multidisciplinary approach. The aim of this study was to analyse results in the real-world management of RCC patients with an extended IVC TT (level II-IV according to the Mayo classification of macroscopic venous invasion in RCC) in terms of pre-, peri- and postoperative outcome, complications and oncologic outcome. Methods We investigated 61 patients with evidence of RCC and an extended TT in the IVC undergoing radical nephrectomy and tumour thrombectomy at our tertiary referral centre. Patients and operative characteristics were recorded and complications were analysed using the Clavien-Dindo classification. Follow-up data were retrieved by contacting the treating outpatient urologists, general practitioners and patients. Results The TT level was II in 36, III in 8 and IV in 17 patients. Complications grade IIIb and higher according to the Clavien-Dindo classification occurred in n = 3 (8.4 %), n = 2 (25.0 %) and n = 5 (29.5 %) patients with level II, III and IV TT, respectively. The overall survival of patients with TT level II, III and IV at 24 months (60 months) was 66.9 % (41.6 %), 83.3 % (83.3 %) and 64.1 % (51.3 %). Presence of primary metastatic disease was the only significant independent predictor for OS. Conclusions Radical nephrectomy with tumour thrombectomy appears to be a feasible and effective treatment option in the management of patients with RCC and an extended IVC TT.

OBJECTIVES Since 1967, the Ross procedure has been performed to treat aortic valve disease using homografts for pulmonary valve replacement. The decellularized Matrix P® prosthesis was developed to overcome (some) limitations of homografts. Until now, the long-term outcome data have been unavailable. METHODS Between 2002 and 2010, the Ross procedures using the Matrix P prosthesis were performed in 492 adult patients (mean age 57.2 ± 10.6 years, range 21-73 years) at our institution. Patient data were prospectively collected and analysed (3617.3 patient-years, mean follow-up 7.7  ±  4.3 years). Completeness of follow-up at 1, 5 and 10 years was 98.4%, 94.5% and 91.0%, respectively. RESULTS Hospital mortality was 3.9% (n  = 19). During follow-up, 121 patients died resulting in a survival rate at 5, 10 and 12.5 years of 82.8  ±  1.7%, 70.4  ±  2.3% and 62.4  ±  2.9%, respectively. Echocardiography revealed a high incidence of relevant dysfunction of the Matrix P prosthesis and subsequent right ventricular failure. Primary reoperation/reintervention was necessary for 150 Matrix P and 48 autografts. Freedom from pulmonary valve reoperation at 5, 10 and 12.5 years was 76.2  ±  2.1%, 58.6  ±  2.9% and 53.4  ±  3.4%, respectively. The autograft function and the left ventricular function showed similar results as previously reported with a freedom from autograft reoperation at 5, 10 and 12.5 years of 91.8  ±  1.4%, 86.1  ±  2.0% and 86.1  ±  2.0%, respectively. CONCLUSIONS The Matrix P prosthesis used for the right ventricular outflow tract reconstruction in the Ross procedure showed unfavourable long-term echocardiographic results with a high rate of reoperation/reintervention for structural pulmonary valve failure. As a consequence, long-term survival of this patient cohort was impaired. Based on these findings, the use of the Matrix P prosthesis for pulmonary valve replacement for Ross procedures in adults should not be recommended.

Background The Ross procedure is an established method to treat aortic valve disease, offering excellent hemodynamic characteristics, growth potential, low risk of thromboembolism and no need for anticoagulation. Limitation of homograft quality and availability led to the use of different stentless xenografts. Long-term outcome and implications are yet to be addressed. Methods Forty five adult patients (mean age 38.8 ± 9.6 years) with aortic valve stenosis and/or insufficiency, who underwent the Ross procedure between 1995 and 2002 were identified for long-term evaluation. Patients younger than 18 years, with previous heart surgery and endocarditis were excluded. Stentless xenografts were used in 22 cases (Group X) and homografts in 23 cases (Group H). After review of the patients' history, morbidity and mortality were analyzed and risk stratification was performed. Results Between groups, baseline characteristics and operative data did not differ significantly. Total follow-up was 621.0 patient-years and 98.8% complete. Overall freedom from reoperation at 15 years was 68.4 ± 10.6% in group X and 85. ± 7.9% in group H (p = 0.09), respectively. Freedom from aortic valve reoperation at 15 years was comparable (83.9 ± 8.5% in group X and 85.3 ± 7.9% in group H, p = 0.61), whereas freedom from pulmonary valve reoperation at 15 years was significantly lower in group X (78.9 ± 9.4% versus 100%, p = 0.02). Long-term survival at 15 years was 79.7 ± 9.3% in group X and 94.4 ± 5.4% in group H (p = 0.07), respectively. Conclusions Stentless xenografts used as pulmonary valve substitute in the Ross procedure led to lower freedom from pulmonary valve reoperation compared with homografts. Additionally, there was a trend to inferior long-term survival with xenografts. Therefore, homografts should remain the preferred option for pulmonary valve replacement in the Ross procedure.

A 73-year-old woman first presented with heart failure, symptom class NYHA III, and fatigue that had gradually worsened over the course of 2 years despite medical outpatient therapy. She had a history of intermittent third-degree atrioventricular block that led to the …

Stentless aortic valve replacements show improved hemodynamics due to larger orifice area and lower transvalvular gradients in short and mid-term follow-up. Hemodynamic long-term behavior and the adaptation of the left ventricle as well as valve-durability in patients aged ≤60 years remains unclear.

Background and aim of the study: The study aim was to evaluate the short-term survival and functional outcome after the Ross procedure, with expanded inclusion criteria.Methods: A total of 91 patients (21 females, 70 males; mean age 57.3 +/- 13.1 years; range: 0.1-74 years) underwent aortic valve replacement (AVR) with a Ross procedure at the authors' institution during the year 2007. The underlying valve diseases were stenosis in 60 patients, regurgitation in 17, and a mixed lesion in 14. Seven patients suffered from acute infective endocarditis, and in five patients the Ross operation was a reoperative procedure. Forty-four patients (48%) underwent surgery in association with concomitant procedures, which included predominantly coronary artery bypass surgery, mitral valve repair or replacement, or procedures of the ascending aorta.Results: The mean cardiopulmonary bypass and aortic cross-clamp times were 147 +/- 31 min (range: 87-246 min) and 124 +/- 26 min (range: 73-195 min), respectively. Hospital mortality was 2.2%. No patient died during the follow up period. The aortic gradient was decreased from 5.1 +/- 2 mmHg at discharge, to 3.2 +/- 1 mmHg during follow up (p<0.05); at the same times, the mean gradient of the decellularized tissue-engineered pulmonary valve was 2.8 +/- 1 mmHg and 2.7 +/- 1 mmHg, respectively. An echocardiographic examination of neo-aortic valve competence at 12 months revealed no or trivial aortic valve regurgitation in 80 patients, and mild (grade 1+) regurgitation in nine patients. No patient required reoperation of the autograft during follow up. Two patients underwent reconstruction of the right ventricular outflow tract. At 12 months' follow up, all patients enjoyed normal social interactions, were in NYHA functional class I or II, and free from complications.Conclusion: The Ross procedure can be offered as an alternative to standard prosthetic AVR with an excellent short-term outcome. The former inclusion/exclusion criteria for this procedure should be re-evaluated.

OBJECTIVE:We sought to determine the comparability of multislice computed tomography (MSCT) and magnetic resonance imaging (MRI) for measuring the aortic valve orifice area (AVA) and grading aortic valve stenosis. MATERIALS AND METHODS:Twenty-seven individuals, among them 18 patients with valvular stenosis, underwent AVA planimetry by both MSCT and MRI. In the subset of patients with valvular stenosis, AVA was also calculated from transthoracic Doppler echocardiography (TTE) using the continuity equation. RESULTS:There was excellent correlation between MSCT and MRI (r = 0.99) and limits of agreement were in an acceptable range (± 0.42 cm(2)) although MSCT yielded a slightly smaller mean AVA than MRI (1.57 ± 0.83 cm(2) vs. 1.67 ± 0.98 cm(2), p < 0.05). However, in the subset of patients with valvular stenosis, the mean AVA was not different between MSCT and MRI (1.05 ± 0.30 cm(2) vs. 1.04 ± 0.39 cm(2); p > 0.05). The mean AVAs on both MSCT and MRI were systematically larger than on TTE (0.88 ± 0.28 cm(2), p < 0.001 each). Using an AVA of 1.0 cm(2) on TTE as reference, the best threshold for detecting severe-to-critical stenosis on MSCT and MRI was an AVA of 1.25 cm(2) and 1.30 cm(2), respectively, resulting in an accuracy of 96% each. CONCLUSION:Our study specifies recent reports on the suitability of MSCT for quantifying AVA. The data presented here suggest that certain methodical discrepancies of AVA measurements exist between MSCT, MRI and TTE. However, MSCT and MRI have shown excellent correlation in AVA planimetry and similar accuracy in grading aortic valve stenosis.

BACKGROUND:Cardiac surgery is increasingly required in octogenarians. These patients frequently present atrial fibrillation (AF), a significant factor for stroke and premature death. During the last decade, AF ablation has become an effective procedure in cardiac surgery. Because the results of concomitant AF ablation in octogenarians undergoing cardiac surgery are still not clear, we evaluated the outcome in these patients.METHODS:Among 200 patients undergoing concomitant AF ablation (87% persistent AF), 28 patients were >/= 80 years (82 +/- 2.4 years). The outcome was analysed by prospective follow up after 3, 6, 12 months and annually thereafter. Freedom from AF was calculated according to the Kaplan-Meier method.RESULTS:Octogenarians were similar to controls regarding AF duration (48 +/- 63.2 versus 63 +/- 86.3 months, n.s.) and left atrial diameter (49 +/- 6.1 versus 49 +/- 8.8 mm, n.s.), but differed in EuroSCORE (17.3 +/- 10.93 versus 7.4 +/- 7.31%, p < 0.001), prevalence of paroxysmal AF (25.0 versus 11.0%, p = 0.042) and aortic valve disease (67.8 versus 28.5%, p < 0.001). ICU stay (8 +/- 16.9 versus 4 +/- 7.2 days, p = 0.027), hospital stay (20 +/- 23.9 versus 14 +/- 30.8 days, p < 0.05), and 30-d-mortality (14.3 versus 4.6%, p = 0.046) were increased. After 12 +/- 6.1 months of follow-up (95% complete), 14 octogenarians (82%) and 101 controls (68%, n.s.) were in sinus rhythm; 59% without antiarrhythmic drugs in either group (n.s.). Sinus rhythm restoration was associated with improved NYHA functional class and renormalization of left atrial size. Cumulative freedom from AF demonstrated no difference between groups. Late mortality was higher in octogenarians (16.7 versus 6.1%, p = 0.065).CONCLUSION:Sinus rhythm restoration rate and functional improvement are satisfactory in octogenarians undergoing concomitant AF ablation. Hence, despite an increased perioperative risk, this procedure should be considered even in advanced age.

Objective: Previous investigations have shown the usefulness of electron-beam computed tomography (EBCT) to describe ventricular diastolic function and to detect constrictive filling pattern. We used EBCT to analyze diastolic function in patients who underwent passive epicardial constraint because data describing ventricular filling in these patients are still incomplete.Methods: Ten patients with dilated cardiomyopathy (group 1) underwent EBCT examination before and again 6 months after surgery. Ten patients with normal diastolic function (group 2) and 5 male patients with constrictive pericarditis (group 3) served for comparison. Volume-time curves throughout the entire diastole were generated, and the rapidity of diastolic filling was assessed by calculating the percent filling fraction at consecutive EBCT frames throughout the diastole. Pericardial thickness was measured in a standardized fashion at different locations around both ventricles.Results: Early left ventricular filling pattern in group I did not change postoperatively (filling fraction at third diastolic frame was 50.0 +/- 15.4% and 53.8 +/- 14.4% before and after surgery, respectively) and was not significantly different from group 2 (48.7 +/- 8.5%). In contrast, in group 3, early left ventricular filling was significantly accelerated (71.4 +/- 9.3%) when compared with groups 1 and 2. A similar pattern was observed for the right ventricle. Pericardial thickness between groups 1 (1.22 +/- 4.22 and 1.43 +/- 0.39 mm before and after surgery, respectively) and 2 (1.38 +/- 0.43 mm) did not differ significantly. In contrast, pericardium in group 3 was significantly thickened (4.93 +/- 1.11 mm) when compared with both groups I and 2.Conclusions: The EBCT identified an abnormal accelerated diastolic filling and thickened pericardium in patients with constrictive pericarditis. Conversely, a normal diastolic filling pattern and pericardial thickness seem to be preserved in patients after passive epicardial constraint, when compared with baseline values and with normal subjects.

BACKGROUND AND AIM OF THE STUDY:Although, in recent years, atrial fibrillation (AF) ablation has become an effective concomitant procedure in cardiac surgery, it is unclear whether the outcome of the procedure is determined by the underlying valve disease.METHODS:Between 2003 and 2005, 191 patients (100 females, 91 males; mean age 70+/-8.7 years) underwent concomitant left atrial (LA) ablation. Among these patients, those with permanent AF (pAF) and mitral (MVD; n = 64), aortic (AVD; n = 37), and combined valve disease (CVD; n = 23) were prospectively studied after three, six and 12 months, and annually thereafter. The predictive values of preoperative variables for postoperative AF were examined.RESULTS:AVD patients were older than MVD patients (74 +/-7.8 versus 66+/-8.6 years; p <0.001), and presented smaller atria (48+/- 5.7 versus 53+/-8.0 mm; p <0.05), but CVD patients were similar to MVD patients in terms of these parameters (age 70+/-9.3 years, LA diameter 54+/-9.6 mm). Ablation caused no injury or death in any of the patients. Within 30 days after surgery, three (4.7%), three (8.1%) and two (8.7%) of the MVD, AVD and CVD patients, respectively, had died (6.4% overall mortality). The sinus rhythm (SR) conversion rate was 76.8, 63.3 and 58.8% (p = NS) after a mean follow up (FU) of 10+/-4.0, 9+/-4.2 and 10+/-3.9 months (p = NS) in the MVD, AVD and CVD groups, respectively. FU was 97% complete. During FU, four (6.6%), two (5.9%) and four (19.0%) MVD, AVD and CVD patients died, respectively. Univariate analysis demonstrated a shorter AF duration (42+/-49.0 versus 85+/-67.2 months; p <0.05) and smaller LA diameter (50+/-8.1 versus 55+/-9.2 mm; p <0.05) in patients with SR versus non-SR. Multivariate analysis revealed AF duration (Odds ratio (OR) 1.01, 95% CI 1.00-1.02, p <0.05) and LA diameter (OR 1.08, 95% CI 1.01-1.15, p <0.05) as independent predictors of SR conversion. Overall, 86% of patients with two or less years' duration of pAF were in SR at FU.CONCLUSION:AF duration and LA diameter, but not the type of valve disease, predict SR conversion after concomitant ablation of pAF in valvular heart surgery.

BACKGROUND AND AIM OF THE STUDY The new Freedom SOLO aortic valve, as a modification of the Pericarbon Freedom stentless valve, requires only one suture line. The study aim was to compare both prostheses with regard to surgical convenience and early postoperative hemodynamics. METHODS In this case-matched study, 90 patients underwent primary elective isolated or combined aortic valve replacement (AVR) between 2001 and 2004. The Freedom SOLO valve was implanted in 30 patients using a supra-annular, subcoronary technique with one continuous subcoronary suture line (group FS). For comparison, the Pericarbon Freedom valve was implanted in 30 patients using an interrupted suture (group PFI), and in 30 patients using a continuous suture line at the inflow site (group PFC). Patient hemodynamics at discharge were investigated by monitoring echocardiographic peak and mean gradients, and regurgitation. RESULTS The mean extracorporeal circulation time (75.5+/-22.7 min in FS; 83.7+/-21.0 min in PFC versus 110.9+/-31.4 min in PFI) and cross-clamp time (56.0+/-18.6 min in FS; 62.2+/-16.2 min in PFC versus 87.7 +/-25.4 min in PFI) were significantly shorter with the continuous implantation techniques. Hemodynamics were most favorable for the Freedom SOLO valve as compared to either implantation technique of the Pericarbon Freedom valve (mean gradient 7.4+/-4.6 mmHg in FS versus 10.6+/-6.0 mmHg in PFC and 11.0+/-5.7 mmHg in PFI). There were no paravalvular leakages or transvalvular regurgitations. CONCLUSION The Freedom SOLO stentless valve is easy to implant and demonstrates superior early postoperative hemodynamics. Due to the reduced cross-clamp time, it also offers an attractive option in isolated and combined AVR.

BACKGROUND:Congestive heart failure (CHF) and atrial fibrillation (AF), both of which cause morbidity and mortality, are mutually promoting diseases. We aimed to evaluate surgical AF ablation in CHF. METHODS AND RESULTS:Among 212 patients (age 69 +/- 8.8 years, 87% with persistent AF) undergoing concomitant left atrial (LA) ablation, 79 (37.3%) presented CHF (n = 62 with a left ventricular ejection fraction [LVEF] 0.31-0.45, n = 17 with an LVEF < or = 0.30). Patients with CHF were similar to controls regarding AF duration (61 +/- 65.1 months vs. 54 +/- 67.2 months, not significant [NS]), LA diameter (49 +/- 7.5 mm vs. 50 +/- 9.2 mm, NS), and heart rate (78 +/- 18.4 min(-1) vs. 81 +/- 21.3 min(-1), NS), but they required more circulatory support (17.7% vs. 1.5%, P < .001) and a longer intensive care unit stay (6 +/- 9.5 days vs. 4 +/- 10.5 days, P = .032). At follow-up after 13 +/- 7.3 months, 42 patients (66%) with CHF and 81 controls (74%, NS) were in sinus rhythm (SR) (55% and 64% without antiarrhythmic drugs, respectively, NS). Univariate and logistic regression analysis revealed that AF duration and LA diameter predicted rhythm outcome but not CHF. In patients with an LVEF of 0.30 or less, SR conversion significantly improved LVEF, New York Heart Association class, and Minnesota Living with Heart Failure score. Kaplan-Meier estimates suggested superior survival of patients with stable SR (100% vs. 73%, log-rank P < .05). CONCLUSIONS:If patients presenting with CHF and AF require cardiac surgery, concomitant AF ablation should be considered, especially if left ventricular function is severely impaired.

Introduction Cardiopulmonary bypass (CPB) induces hemodilutional anemia, which frequently requires the transfusion of blood products. The objective of this study was to evaluate oxygen delivery and consumption and clinical outcome in low risk patients who were allocated to an hematocrit (Hct) of 20% versus 25% during normothermic CPB for elective coronary artery bypass graft (CABG) surgery.Methods This study was a prospective, randomized and controlled trial. Patients were subjected to normothermic CPB (35 to 36 degrees C) and were observed until discharge from the intensive care unit (ICU). Outcome measures were calculated whole body oxygen delivery, oxygen consumption and clinical outcome. A nonparametric multivariate analysis of variance for repeated measurements and small sample sizes was performed.Results In a total of 54 patients (25% Hct, n = 28; 20% Hct, n = 26), calculated oxygen delivery ( p = 0.11), oxygen consumption ( p = 0.06) and blood lactate ( p = 0.60) were not significantly different between groups. Clinical outcomes were not different between groups.Conclusion These data indicate that an Hct of 20% during normothermic CPB maintained calculated whole body oxygen delivery above a critical level after elective CABG surgery in low risk patients. The question of whether a transfusion trigger in excess of 20% Hct during normothermic CPB is still supported requires a larger prospective and randomized trial.